Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial
Neuromuscular Disorders · 2023
DOI: 10.1016/j.nmd.2023.06.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuromuscular Disorders, 2023. Verfasst von Richard D Shell und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nationwide Children's Hospital, Columbus, OH, USA; Department of Pediatrics, The Ohio State University, Columbus, OH, USA. Electronic address: richar…. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Deglutition Disorders, Spinal Muscular Atrophies of Childhood. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Gene Therapies.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nationwide Children's Hospital, Columbus, OH, USA; Department of Pediatrics, The Ohio State University, Columbus, OH, USA. Electronic address: richard.shell@nationwidechildrens.org.
- University of Minnesota, Minneapolis, MN, USA.
- Primary Children's Hospital, Salt Lake City, UT, USA.
- Stanford University School of Medicine, Stanford, CA, USA.
- The Dubowitz Neuromuscular Centre, Developmental Neuroscience Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK; NIHR Great Ormond Street Hospital Biomedical Research Centre…
- Novartis Gene Therapies, Inc., Cambridge, UK.
Förderung
- Novartis Gene Therapies
Zitieren
APA
Shell, R. D., McGrattan, K. E., Hurst-Davis, R., Young, S. D., Baranello, G., Lavrov, A., O'Brien, E., Wallach, S., LaMarca, N., Reyna, S. P., & Darras, B. T. (2023). Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial. Neuromuscular Disorders. https://doi.org/10.1016/j.nmd.2023.06.005
Vancouver
Shell RD, McGrattan KE, Hurst-Davis R, Young SD, Baranello G, Lavrov A, et al. Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial. Neuromuscular Disorders. 2023. doi:10.1016/j.nmd.2023.06.005
BibTeX
@article{Shell2023,
author = {Shell, Richard D and McGrattan, Katlyn E and Hurst-Davis, Rebecca and Young, Sally Dunaway and Baranello, Giovanni and Lavrov, Arseniy and O'Brien, Eamonn and Wallach, Shiri and LaMarca, Nicole and Reyna, Sandra P and Darras, Basil T},
title = {Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial},
journal = {Neuromuscular Disorders},
year = {2023},
doi = {10.1016/j.nmd.2023.06.005}
}
EUVIMED